On the other hand, TP53 mutations may be helpful in predicting poor prognosis in early breast cancer patients with Luminal A/B tumors and probably with TNBC, while immunopositivity for p53 protein may be predictive for adjuvant trastuzumab benefit. This evidence concerns the gene TP53 and breast cancer.